Physician profile

Muhammad Talib

Pulmonary Disease · Live Oak, TX

NPI 1700855640

$7,124.44

in general payments reported to CMS, 2019-2025

40 companies · $1,829 in 2025

The $1,829 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,724.41

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $1,201.08 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Olympus Corporation of The Americas $989.98 2019
Astrazeneca Pharmaceuticals LP $612.17 2019-2025 Fasenra, Tezspire, Airsupra
Boehringer Ingelheim Pharmaceuticals, INC. $585.72 2019-2025 Ofev, Jascayd
Actelion Pharmaceuticals US, INC. $504.44 2019-2025 Uptravi, Opsumit, Opsynvi
Grifols USA, LLC $455.15 2019-2025 Prolastin-C Liquid
Insmed, INC. $274.66 2023-2025 Arikayce, Brinsupri
Regeneron Healthcare Solutions, INC. $227.23 2022-2025 Dupixent
Jazz Pharmaceuticals INC. $226.45 2019-2025 Xywav
Takeda Pharmaceuticals U.S.A., INC. $172.12 2023-2025 Glassia
Electromed, INC. $150.67 2022-2025 Smartvest
Baxter Healthcare $139.39 2022-2025 Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System
Harmony Biosciences LLC $138.86 2021-2024
Genzyme Corporation $138.82 2019-2025
Philips North America LLC $135.39 2021-2023
Show all 40 companies
CompanyGeneral paymentsYearsTop products
United Therapeutics Corporation $128.06 2019-2025 Tyvaso, Tyvaso
Advanced Respiratory, INC $103.49 2020-2021
Avadel Cns Pharmaceuticals, LLC $93.65 2025 Lumryz
Gilead Sciences, INC. $90.95 2019-2021
Mylan Specialty L.P. $79.77 2019-2021
Lilly USA, LLC $67.03 2025 Zepbound, Mounjaro
Axsome Therapeutics, INC. $60.68 2023-2025 Sunosi
Csl Behring $57.33 2020
Mallinckrodt Hospital Products INC. $56.12 2024-2025 Acthar
Fisher & Paykel Healthcare INC $52.42 2022-2023 Fisher & Paykel Healthcare
Bayer Healthcare Pharmaceuticals INC. $42.91 2023
Pulmonx Corporation $37.34 2022
Inogen, INC. $37.26 2022-2023 Inogen
Liquidia Technologies, INC. $30.89 2025 Yutrepia
Alk-Abello, INC $29.36 2024 Ragwitek, Grastek, Odactra
Portola Pharmaceuticals, LLC $28.80 2019
Apria Healthcare LLC $25.45 2021
Inspire Medical Systems, INC. $24.02 2025 Inspire
3b Medical, INC. $23.58 2024 Luna
Merck Sharp & Dohme LLC $21.19 2023
Shire North American Group INC $19.07 2019
Itamar Medical INC $16.96 2022
Genentech USA, INC. $15.95 2019
Janssen Pharmaceuticals, INC $15.62 2021
Verona Pharma, INC. $14.41 2025 Ohtuvayre

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Muhammad Talib

$7,124.44

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $1,829 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/122765/muhammad-talib

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.